Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy
Background. We wanted to investigate whether treatment with losartan, an angiotensin II receptor blocker, induced regression of carotid artery hypertrophy as compared to the beta-receptor blocker, atenolol. Methods. In 45 patients recruited for the LIFE Study with stage II-III hypertension and ECG l...
Gespeichert in:
| Veröffentlicht in: | Blood pressure 2005-07, Vol.14 (3), p.177-183 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 183 |
|---|---|
| container_issue | 3 |
| container_start_page | 177 |
| container_title | Blood pressure |
| container_volume | 14 |
| creator | Olsen, Michael H. Wachtell, Kristian Neland, Keld Bella, Jonathan N. Rokkedal, Jens Dige-Petersen, Harriet Ibsen, Hans |
| description | Background. We wanted to investigate whether treatment with losartan, an angiotensin II receptor blocker, induced regression of carotid artery hypertrophy as compared to the beta-receptor blocker, atenolol. Methods. In 45 patients recruited for the LIFE Study with stage II-III hypertension and ECG left ventricular (LV) hypertrophy, we measured blood pressure, intima-media thickness (IMT) and lumen in the common carotid arteries by ultrasound, and minimal forearm vascular resistance (MFVR) by plethysmography, after 2 weeks of placebo treatment and after 1, 2 and 3 years of anti-hypertensive treatment with either atenolol- or losartan-based regimens. We measured the same parameters in 26 normal subjects matched for age and gender. Results. The patients had as compared to normotensive controls higher IMT (0.87 vs 0.76 mm, p = 0.001) and intima-media cross-sectional area (IMA) (19.7 vs 15.5 mm2, p |
| doi_str_mv | 10.1080/08037050510034185 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_16036498</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68062461</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-71ed876cf87b642748a5825829795bd4563177ead22739fc6f0750c0ccbc371d3</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVpaDZJf0AvRafenIwsW7JpLiHkCxZySc5Clsasg1baSjLB_z4KuxBKIDBiDvO8L-Ih5BeDcwYdXJTHJbTQMgDesK79RlZMtKxifd9_J6v3e1UAdkxOUnoBYJwD_CDHTAAXTd-tyLgOScesPR3mTH3IVGf0wQVHI9rZIDU6hjxZWiiMC90sO4w5ht1moZOnmBL6PGl3OKBPU_Dn9IquH25vaJqHlGe7nJGjUbuEPw_7lDzf3jxd31frx7uH66t1ZbiUuZIMbSeFGTs5iKaWTafbri7Ty74dbNMKzqREbeta8n40YgTZggFjhlLALD8lf_a9uxj-zZiy2k7JoHPaY5iTEh2IuhGsgGwPmhhSijiqXZy2Oi6KgXqXqz7JLZnfh_J52KL9SBxsFuByD0x-DHGrX0N0VmW9uBDHqL2ZkuJf9f_9L75B7fKm-Ef1Euboi7gvfvcGF-maIw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68062461</pqid></control><display><type>article</type><title>Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Taylor & Francis Journals Complete</source><creator>Olsen, Michael H. ; Wachtell, Kristian ; Neland, Keld ; Bella, Jonathan N. ; Rokkedal, Jens ; Dige-Petersen, Harriet ; Ibsen, Hans</creator><creatorcontrib>Olsen, Michael H. ; Wachtell, Kristian ; Neland, Keld ; Bella, Jonathan N. ; Rokkedal, Jens ; Dige-Petersen, Harriet ; Ibsen, Hans</creatorcontrib><description>Background. We wanted to investigate whether treatment with losartan, an angiotensin II receptor blocker, induced regression of carotid artery hypertrophy as compared to the beta-receptor blocker, atenolol. Methods. In 45 patients recruited for the LIFE Study with stage II-III hypertension and ECG left ventricular (LV) hypertrophy, we measured blood pressure, intima-media thickness (IMT) and lumen in the common carotid arteries by ultrasound, and minimal forearm vascular resistance (MFVR) by plethysmography, after 2 weeks of placebo treatment and after 1, 2 and 3 years of anti-hypertensive treatment with either atenolol- or losartan-based regimens. We measured the same parameters in 26 normal subjects matched for age and gender. Results. The patients had as compared to normotensive controls higher IMT (0.87 vs 0.76 mm, p = 0.001) and intima-media cross-sectional area (IMA) (19.7 vs 15.5 mm2, p<0.001). Systolic and diastolic blood pressures were reduced to the same degree in patients treated with losartan as compared to atenolol. However, IMA decreased significantly only in patients treated with losartan (19.2 vs 17.6 mm2, p = 0.001) and the average relative decrease in IMA during the 3 years of treatment was significantly higher in patients treated with losartan as compared to atenolol (−7.4 vs −2.0%, p<0.05). Conclusion. Patients with hypertension and LV hypertrophy had hypertrophy of the common carotid arteries. Losartan, but not atenolol, induced regression of this hypertrophy. Because carotid artery hypertrophy has been associated with strokes, our findings may explain the lower incidence of strokes in the LIFE study in patients treated with losartan as compared to atenolol.</description><identifier>ISSN: 0803-7051</identifier><identifier>EISSN: 1651-1999</identifier><identifier>DOI: 10.1080/08037050510034185</identifier><identifier>PMID: 16036498</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Aged ; Angiotensin II receptor blockers ; Atenolol - therapeutic use ; beta-receptor blockers ; Blood Pressure - drug effects ; Carotid Arteries - diagnostic imaging ; Carotid Arteries - drug effects ; Carotid Arteries - pathology ; common carotid artery ; Female ; Humans ; hypertension ; Hypertension - diagnostic imaging ; Hypertension - drug therapy ; Hypertension - physiopathology ; left ventricular hypertrophy ; Losartan - therapeutic use ; Male ; minimal forearm vascular resistance ; Time ; Treatment Outcome ; Tunica Intima - diagnostic imaging ; Tunica Intima - drug effects ; Tunica Intima - pathology ; Ultrasonography ; vascular hypertrophy</subject><ispartof>Blood pressure, 2005-07, Vol.14 (3), p.177-183</ispartof><rights>2005 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-71ed876cf87b642748a5825829795bd4563177ead22739fc6f0750c0ccbc371d3</citedby><cites>FETCH-LOGICAL-c377t-71ed876cf87b642748a5825829795bd4563177ead22739fc6f0750c0ccbc371d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/08037050510034185$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/08037050510034185$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,59623,60412,61197,61378</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16036498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Olsen, Michael H.</creatorcontrib><creatorcontrib>Wachtell, Kristian</creatorcontrib><creatorcontrib>Neland, Keld</creatorcontrib><creatorcontrib>Bella, Jonathan N.</creatorcontrib><creatorcontrib>Rokkedal, Jens</creatorcontrib><creatorcontrib>Dige-Petersen, Harriet</creatorcontrib><creatorcontrib>Ibsen, Hans</creatorcontrib><title>Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy</title><title>Blood pressure</title><addtitle>Blood Press</addtitle><description>Background. We wanted to investigate whether treatment with losartan, an angiotensin II receptor blocker, induced regression of carotid artery hypertrophy as compared to the beta-receptor blocker, atenolol. Methods. In 45 patients recruited for the LIFE Study with stage II-III hypertension and ECG left ventricular (LV) hypertrophy, we measured blood pressure, intima-media thickness (IMT) and lumen in the common carotid arteries by ultrasound, and minimal forearm vascular resistance (MFVR) by plethysmography, after 2 weeks of placebo treatment and after 1, 2 and 3 years of anti-hypertensive treatment with either atenolol- or losartan-based regimens. We measured the same parameters in 26 normal subjects matched for age and gender. Results. The patients had as compared to normotensive controls higher IMT (0.87 vs 0.76 mm, p = 0.001) and intima-media cross-sectional area (IMA) (19.7 vs 15.5 mm2, p<0.001). Systolic and diastolic blood pressures were reduced to the same degree in patients treated with losartan as compared to atenolol. However, IMA decreased significantly only in patients treated with losartan (19.2 vs 17.6 mm2, p = 0.001) and the average relative decrease in IMA during the 3 years of treatment was significantly higher in patients treated with losartan as compared to atenolol (−7.4 vs −2.0%, p<0.05). Conclusion. Patients with hypertension and LV hypertrophy had hypertrophy of the common carotid arteries. Losartan, but not atenolol, induced regression of this hypertrophy. Because carotid artery hypertrophy has been associated with strokes, our findings may explain the lower incidence of strokes in the LIFE study in patients treated with losartan as compared to atenolol.</description><subject>Aged</subject><subject>Angiotensin II receptor blockers</subject><subject>Atenolol - therapeutic use</subject><subject>beta-receptor blockers</subject><subject>Blood Pressure - drug effects</subject><subject>Carotid Arteries - diagnostic imaging</subject><subject>Carotid Arteries - drug effects</subject><subject>Carotid Arteries - pathology</subject><subject>common carotid artery</subject><subject>Female</subject><subject>Humans</subject><subject>hypertension</subject><subject>Hypertension - diagnostic imaging</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - physiopathology</subject><subject>left ventricular hypertrophy</subject><subject>Losartan - therapeutic use</subject><subject>Male</subject><subject>minimal forearm vascular resistance</subject><subject>Time</subject><subject>Treatment Outcome</subject><subject>Tunica Intima - diagnostic imaging</subject><subject>Tunica Intima - drug effects</subject><subject>Tunica Intima - pathology</subject><subject>Ultrasonography</subject><subject>vascular hypertrophy</subject><issn>0803-7051</issn><issn>1651-1999</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1r3DAQhkVpaDZJf0AvRafenIwsW7JpLiHkCxZySc5Clsasg1baSjLB_z4KuxBKIDBiDvO8L-Ih5BeDcwYdXJTHJbTQMgDesK79RlZMtKxifd9_J6v3e1UAdkxOUnoBYJwD_CDHTAAXTd-tyLgOScesPR3mTH3IVGf0wQVHI9rZIDU6hjxZWiiMC90sO4w5ht1moZOnmBL6PGl3OKBPU_Dn9IquH25vaJqHlGe7nJGjUbuEPw_7lDzf3jxd31frx7uH66t1ZbiUuZIMbSeFGTs5iKaWTafbri7Ty74dbNMKzqREbeta8n40YgTZggFjhlLALD8lf_a9uxj-zZiy2k7JoHPaY5iTEh2IuhGsgGwPmhhSijiqXZy2Oi6KgXqXqz7JLZnfh_J52KL9SBxsFuByD0x-DHGrX0N0VmW9uBDHqL2ZkuJf9f_9L75B7fKm-Ef1Euboi7gvfvcGF-maIw</recordid><startdate>20050701</startdate><enddate>20050701</enddate><creator>Olsen, Michael H.</creator><creator>Wachtell, Kristian</creator><creator>Neland, Keld</creator><creator>Bella, Jonathan N.</creator><creator>Rokkedal, Jens</creator><creator>Dige-Petersen, Harriet</creator><creator>Ibsen, Hans</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050701</creationdate><title>Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy</title><author>Olsen, Michael H. ; Wachtell, Kristian ; Neland, Keld ; Bella, Jonathan N. ; Rokkedal, Jens ; Dige-Petersen, Harriet ; Ibsen, Hans</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-71ed876cf87b642748a5825829795bd4563177ead22739fc6f0750c0ccbc371d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Aged</topic><topic>Angiotensin II receptor blockers</topic><topic>Atenolol - therapeutic use</topic><topic>beta-receptor blockers</topic><topic>Blood Pressure - drug effects</topic><topic>Carotid Arteries - diagnostic imaging</topic><topic>Carotid Arteries - drug effects</topic><topic>Carotid Arteries - pathology</topic><topic>common carotid artery</topic><topic>Female</topic><topic>Humans</topic><topic>hypertension</topic><topic>Hypertension - diagnostic imaging</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - physiopathology</topic><topic>left ventricular hypertrophy</topic><topic>Losartan - therapeutic use</topic><topic>Male</topic><topic>minimal forearm vascular resistance</topic><topic>Time</topic><topic>Treatment Outcome</topic><topic>Tunica Intima - diagnostic imaging</topic><topic>Tunica Intima - drug effects</topic><topic>Tunica Intima - pathology</topic><topic>Ultrasonography</topic><topic>vascular hypertrophy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Olsen, Michael H.</creatorcontrib><creatorcontrib>Wachtell, Kristian</creatorcontrib><creatorcontrib>Neland, Keld</creatorcontrib><creatorcontrib>Bella, Jonathan N.</creatorcontrib><creatorcontrib>Rokkedal, Jens</creatorcontrib><creatorcontrib>Dige-Petersen, Harriet</creatorcontrib><creatorcontrib>Ibsen, Hans</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood pressure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Olsen, Michael H.</au><au>Wachtell, Kristian</au><au>Neland, Keld</au><au>Bella, Jonathan N.</au><au>Rokkedal, Jens</au><au>Dige-Petersen, Harriet</au><au>Ibsen, Hans</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy</atitle><jtitle>Blood pressure</jtitle><addtitle>Blood Press</addtitle><date>2005-07-01</date><risdate>2005</risdate><volume>14</volume><issue>3</issue><spage>177</spage><epage>183</epage><pages>177-183</pages><issn>0803-7051</issn><eissn>1651-1999</eissn><abstract>Background. We wanted to investigate whether treatment with losartan, an angiotensin II receptor blocker, induced regression of carotid artery hypertrophy as compared to the beta-receptor blocker, atenolol. Methods. In 45 patients recruited for the LIFE Study with stage II-III hypertension and ECG left ventricular (LV) hypertrophy, we measured blood pressure, intima-media thickness (IMT) and lumen in the common carotid arteries by ultrasound, and minimal forearm vascular resistance (MFVR) by plethysmography, after 2 weeks of placebo treatment and after 1, 2 and 3 years of anti-hypertensive treatment with either atenolol- or losartan-based regimens. We measured the same parameters in 26 normal subjects matched for age and gender. Results. The patients had as compared to normotensive controls higher IMT (0.87 vs 0.76 mm, p = 0.001) and intima-media cross-sectional area (IMA) (19.7 vs 15.5 mm2, p<0.001). Systolic and diastolic blood pressures were reduced to the same degree in patients treated with losartan as compared to atenolol. However, IMA decreased significantly only in patients treated with losartan (19.2 vs 17.6 mm2, p = 0.001) and the average relative decrease in IMA during the 3 years of treatment was significantly higher in patients treated with losartan as compared to atenolol (−7.4 vs −2.0%, p<0.05). Conclusion. Patients with hypertension and LV hypertrophy had hypertrophy of the common carotid arteries. Losartan, but not atenolol, induced regression of this hypertrophy. Because carotid artery hypertrophy has been associated with strokes, our findings may explain the lower incidence of strokes in the LIFE study in patients treated with losartan as compared to atenolol.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>16036498</pmid><doi>10.1080/08037050510034185</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0803-7051 |
| ispartof | Blood pressure, 2005-07, Vol.14 (3), p.177-183 |
| issn | 0803-7051 1651-1999 |
| language | eng |
| recordid | cdi_pubmed_primary_16036498 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Taylor & Francis Journals Complete |
| subjects | Aged Angiotensin II receptor blockers Atenolol - therapeutic use beta-receptor blockers Blood Pressure - drug effects Carotid Arteries - diagnostic imaging Carotid Arteries - drug effects Carotid Arteries - pathology common carotid artery Female Humans hypertension Hypertension - diagnostic imaging Hypertension - drug therapy Hypertension - physiopathology left ventricular hypertrophy Losartan - therapeutic use Male minimal forearm vascular resistance Time Treatment Outcome Tunica Intima - diagnostic imaging Tunica Intima - drug effects Tunica Intima - pathology Ultrasonography vascular hypertrophy |
| title | Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T00%3A08%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Losartan%20but%20not%20atenolol%20reduce%20carotid%20artery%20hypertrophy%20in%20essential%20hypertension.%20A%20LIFE%20substudy&rft.jtitle=Blood%20pressure&rft.au=Olsen,%20Michael%20H.&rft.date=2005-07-01&rft.volume=14&rft.issue=3&rft.spage=177&rft.epage=183&rft.pages=177-183&rft.issn=0803-7051&rft.eissn=1651-1999&rft_id=info:doi/10.1080/08037050510034185&rft_dat=%3Cproquest_pubme%3E68062461%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68062461&rft_id=info:pmid/16036498&rfr_iscdi=true |